Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001384954 | SCV001584657 | pathogenic | Neurofibromatosis, type 1 | 2020-01-31 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). Experimental studies have shown that this variant disrupts mRNA splicing (PMID: 23913538). This variant has been observed in individual(s) with clinical features of neurofibromatosis type I (PMID: 23913538, 7981679). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 38 of the NF1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |
Baylor Genetics | RCV003469710 | SCV004198989 | pathogenic | Juvenile myelomonocytic leukemia | 2022-03-30 | criteria provided, single submitter | clinical testing |